Answers are grounded in this paper and cite their sources.
BACKGROUND: The majority of patients with coronavirus disease 2019 (COVID-19) have good prognoses, but some develop a critical illness that can lead to death. Evidence shows severe acute respiratory syndrome is closely related to the induced cytokine storm. Interleukin-6 is a key player; its role in systemic inflammation is well known. AIM: To evaluate the effect of tocilizumab (TCZ), an interleukin-6 receptor antagonist, on the outcomes for patients with COVID-19 pneumonia. METHODS: June 2020 for observational or prospective studies reporting results of hospitalized adult patients with COVID-19 infection treated with TCZ. Effect sizes were reported as odds ratios (ORs) with 95% confidence intervals (CIs), and an OR less than 1 was associated with a better outcome in those treated with TCZ. CONCLUSION: In COVID-19-infected patients treated with TCZ, outcome may be improved compared to those not treated with TCZ.
No takes yet. Share an insight, caveat, or question.
Petrelli et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: